INMB

4.40

0.45% -0.02

Dopo l'orario di chiusura: 4.40

Inmune Bio Inc (INMB)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$4.42

Aprire:

$4.36

Volume 24 ore:

394.91K

Relative Volume:

1.69

Capitalizzazione di mercato:

$97.56M

Reddito:

$155.00K

Utile/perdita netta:

$-30.01M

Rapporto P/E:

-2.8947

EPS:

-1.52

Flusso di cassa netto:

$-11.98M

1 W Prestazione:

-7.37%

1M Prestazione:

-3.51%

6M Prestazione:

-42.86%

1 anno Prestazione:

-55.73%

Intervallo 1D:

$4.32

$4.60

Intervallo di 1 settimana:

$4.32

$5.16

Portata 52W:

$4.32

$14.74

Inmune Bio Inc Stock (INMB) Company Profile

Nome

Inmune Bio Inc

Settore

Healthcare (1176)

Industria

Biotechnology (673)

Telefono

(858) 964-3720

Indirizzo

225 NE MIZNER BLVD, SUITE 640, BOCA RATON, CA

Dipendente

Cinguettio

@INmuneBio

Prossima data di guadagno

2024-10-31

Ultimi documenti SEC

INMB's Discussions on Twitter

Confronta INMB con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
INMB Inmune Bio Inc	4.40	97.56M	155.00K	-30.01M	-11.98M	-1.67
VRTX Vertex Pharmaceuticals Inc	397.27	102.31B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	701.85	77.13B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	623.82	37.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.44	31.66B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.08	27.11B	3.30B	-501.07M	1.03B	-2.1146

Inmune Bio Inc Stock (INMB) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-10-21	Iniziato	Alliance Global Partners	Buy
2024-09-27	Iniziato	Raymond James	Outperform
2024-08-22	Iniziato	Scotiabank	Sector Outperform
2023-06-01	Iniziato	Robert W. Baird	Outperform
2022-05-24	Downgrade	B. Riley Securities	Buy → Neutral
2021-07-07	Reiterato	Maxim Group	Buy
2021-04-21	Iniziato	B. Riley Securities	Buy
2021-01-22	Reiterato	Maxim Group	Buy
2020-09-01	Iniziato	BTIG Research	Buy
2020-07-15	Reiterato	H.C. Wainwright	Buy

Mostra tutto

Inmune Bio Inc Borsa (INMB) Ultime notizie

Dec 20, 2024

Charles Schwab Investment Management Inc. Trims Stock Holdings in INmune Bio, Inc. (NASDAQ:INMB) - Defense World

Dec 20, 2024

INmune Bio stock hits 52-week low at $4.44 amid market challenges - Investing.com Canada

Dec 20, 2024

INmune Bio stock hits 52-week low at $4.44 amid market challenges By Investing.com - Investing.com South Africa

Dec 20, 2024

Dec 16, 2024

Institutions along with retail investors who hold considerable shares inINmune Bio, Inc. (NASDAQ:INMB) come under pressure; lose 11% of holdings value - Simply Wall St

Dec 16, 2024

Dec 11, 2024

Learn to Evaluate (INMB) using the Charts - Stock Traders Daily

Dec 11, 2024

Dec 10, 2024

INmune Bio extends rights agreement to 2025 - Investing.com India

Dec 10, 2024

INmune Bio Inc. Completes Repayment of Silicon Valley Bank Debt - The Manila Times

Dec 10, 2024

INmune Bio Strengthens Balance Sheet Ahead of Crucial Alzheimer's Trial Data, Clears $15M Debt - StockTitan

Dec 10, 2024

Dec 09, 2024

INmune Bio extends rights agreement to 2025 By Investing.com - Investing.com Nigeria

Dec 09, 2024

INmune Bio Partners with OmniScience, Deploys GenAI Platform for Landmark Alzheimer's Trial - StockTitan

Dec 04, 2024

Nov 27, 2024

Elevai Labs, Inc. signed a license agreement to acquire a Worldwide License Agreement for Proprietary Stem Cell Manufacturing Technology from INmune Bio, Inc.. - Marketscreener.com

Nov 27, 2024

INmune Bio (NASDAQ:INMB) Trading 1.7% Higher – Should You Buy? - Defense World

Nov 27, 2024

INmune Bio (NASDAQ:INMB) Trading 1.7% HigherWhat's Next? - MarketBeat

Nov 27, 2024

Nov 20, 2024

Scotiabank Initiates Coverage of INmune Bio (INMB) with Sector Outperform Recommendation - MSN

Nov 20, 2024

Nov 19, 2024

INmune Bio stock hits 52-week low at $4.76 amid market challenges - Investing.com

Nov 19, 2024

(INMB) Trading Report - Stock Traders Daily

Nov 19, 2024

Nov 13, 2024

INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimer's Disease - Marketscreener.com

Nov 13, 2024

INmune Bio Hits Major Milestone: 208 Patients Enrolled in Phase 2 Alzheimer's Trial | INMB Stock News - StockTitan

Nov 13, 2024

Inmune Bio Emerges as Biotech Innovator in 2023 - TipRanks

Nov 13, 2024

Nov 05, 2024

INmune Bio, Inc. (NASDAQ:INMB) Q3 2024 Earnings Call Transcript - MSN

Nov 05, 2024

Nov 03, 2024

INmune Bio (NASDAQ:INMB) Releases Quarterly Earnings Results, Misses Estimates By $0.11 EPS - MarketBeat

Nov 03, 2024

Is INmune Bio (NASDAQ:INMB) Using Debt In A Risky Way? - Simply Wall St

Nov 03, 2024

INmune Bio Third Quarter 2024 Earnings: US$0.60 loss per share (vs US$0.48 loss in 3Q 2023) - Yahoo Finance UK

Nov 03, 2024

Nov 01, 2024